Single center, dose escalating, safety, tolerability, and pharmacokinetic study of QR-333 in subjects with diabetic peripheral neuropathy
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2006
At a glance
- Drugs QR 333 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Pharmacokinetics
- Sponsors The Quigley Corporation
- 26 Sep 2006 Results have been reported.
- 20 Jun 2006 New trial record.